Thursday, February 28, 2013

FDA APPROVES ONCE - MONTHLY ABILIFY MAINTENA ™ (ARIPIPRAZOLE) FOR EXTENDED - RELEASE INJECTABLE SUSPENSION FOR THE TREATMENT OF SCHIZOPHRENIA


Otsuka Pharmaceutical Co.,Ltd.(Otsuka) and H. Lundbeck A/S (Lundbeck)announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole)for extend
ed-release injectable suspension, an intramuscular(IM) depot formulation indicated for the
treatment of schizophrenia.
ABILIFY MAINTENA will be the first commercialized product from the long-term global alliance between Otsuka and Lundbeck to develop CNS medicines worldwide.The companies expect the product will be available to patients in the U.S. beginning March 18

,